When a medication is taken by tens of millions of people, cancer risk becomes one of the most scrutinized safety questions. For GLP-1 medications, that scrutiny has produced a complex but largely reassuring picture: the most rigorous evidence to date shows that GLP-1 users have lower overall cancer rates, with one notable exception that requires context.
The Big Picture: 17% Lower Overall Cancer Risk
The most comprehensive study on this question was published in JAMA Oncology in October 2025. Researchers at Indiana University and the University of Florida analyzed data from over 86,000 matched adults in the OneFlorida+ network (covering 14 health systems and approximately 20 million patients). They compared cancer incidence between GLP-1 users and eligible nonusers from 2014 to 2024.
The headline finding: GLP-1 users had a 17% lower overall risk of developing cancer compared to nonusers (hazard ratio 0.83, 95% CI 0.76-0.91, p=0.002). Cancer incidence was 13.6 per 1,000 person-years in GLP-1 users versus 16.4 per 1,000 person-years in nonusers.
Several specific cancer types showed statistically significant reductions:
| Cancer Type | Risk Reduction | Evidence Strength |
|---|---|---|
| Overall (14 cancer types) | 17% | Strong (86,000+ patients) |
| Hepatocellular (liver) | 58% | Strong (multiple meta-analyses) |
| Ovarian | 47% | Moderate |
| Meningioma | 31% | Moderate |
| Endometrial | 25% | Moderate |
| Colorectal | 18-43% | Strong (2M+ patients) |
These reductions make biological sense. Obesity is a well-established risk factor for many of these cancers, and significant weight loss—regardless of how it’s achieved—is associated with reduced cancer incidence. GLP-1 medications also reduce chronic inflammation (measured by CRP and other markers), and chronic inflammation is a known driver of cancer development.
The Thyroid Question: A Real Signal That Needs Context
The one area of genuine concern involves thyroid cancer. A 2025 meta-analysis of randomized controlled trials by Silverii et al., published in Diabetes, Obesity and Metabolism, found a statistically significant 55% increased risk of thyroid cancer in patients receiving GLP-1 medications compared to those on placebo or other diabetes drugs.
This finding requires important context:
- Absolute risk is very low: Thyroid cancer is rare, occurring in approximately 1.1% of the general population over a lifetime. Even a 55% relative increase translates to a very small absolute increase in risk.
- Detection bias is possible: Patients on GLP-1 medications receive more frequent medical monitoring, which may lead to earlier detection of thyroid nodules that would otherwise have gone undiagnosed. This “surveillance effect” could inflate the apparent risk.
- Animal vs. human data: The thyroid concern originally arose from rodent studies where liraglutide caused C-cell hyperplasia and medullary thyroid carcinoma in rats and mice. However, rodent thyroid C-cells have significantly higher GLP-1 receptor expression than human C-cells, making the animal model less directly applicable.
- Novo Nordisk’s own analysis (2026): A comprehensive review published by Vilsbøll et al. in late 2025 examined data from 93 clinical trials, post-marketing surveillance, and the US MarketScan database. This analysis found no consistent signal for increased thyroid cancer risk with liraglutide or semaglutide when compared to SGLT2 inhibitor users.
- The semaglutide SELECT trial: With 17,604 patients followed for a mean of 40 months, SELECT did not show increased thyroid cancer incidence with semaglutide compared to placebo.
Current FDA Guidance
GLP-1 medications carry an FDA black box warning stating they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This precautionary warning has been in place since the first GLP-1 approvals and remains unchanged. It is based on the animal data, not on confirmed human cases.
Liver Cancer: A Significant Protective Effect
One of the most striking findings across multiple studies is a consistent and large reduction in liver cancer risk among GLP-1 users. A meta-analysis by Pasta et al. found that GLP-1 therapy reduced hepatocellular carcinoma risk by 58% compared to insulin or other blood-sugar-lowering drugs.
This makes particular sense given that GLP-1 medications directly address metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH—conditions that dramatically increase liver cancer risk. By resolving fatty liver disease and reducing liver inflammation, GLP-1s appear to interrupt the pathway from chronic liver disease to cancer.
Colorectal Cancer: Weight Loss Plus Anti-Inflammatory Effects
A meta-analysis of over 2 million patients found that colorectal cancer risk was significantly lower in GLP-1 users compared to those taking other diabetes medications. The protective effect was particularly notable when compared to insulin users (43% lower risk) and TZD users (18% lower risk).
Interestingly, one meta-analysis of shorter-duration clinical trials initially suggested a slight increase in colorectal cancer diagnoses in GLP-1 groups. Researchers believe this may reflect a detection bias: GLP-1 medications frequently cause GI side effects (nausea, diarrhea), which can prompt diagnostic workups (colonoscopies) that detect cancers earlier. In longer-term observational studies, the net effect consistently favors protection.
Preclinical Research: Direct Anti-Tumor Effects
Beyond the epidemiological data, laboratory research has uncovered potential mechanisms by which GLP-1 receptor activation may directly suppress tumors:
- Pancreatic cancer: Semaglutide slowed growth of pancreatic cancer cells in mouse models, reduced collagen deposition around tumors, and facilitated immune cell infiltration. The triple agonist retatrutide showed even stronger anti-tumor effects.
- Thyroid cancer (paradoxically): In preclinical models, semaglutide actually suppressed thyroid cancer cell growth in mice, despite the epidemiological signal in humans. The mechanism appeared to be immune-mediated rather than a direct effect on cancer cells.
- Breast cancer: One study found semaglutide enhanced acquired antitumor immunity in breast cancer models, though human data is limited.
These preclinical findings suggest that GLP-1 receptor activation may have genuine anti-cancer properties through immune modulation and metabolic reprogramming—but much more research is needed before drawing clinical conclusions.
What This Means for You
The current evidence, taken as a whole, is reassuring for most patients:
- Overall cancer risk appears to decrease with GLP-1 use, likely driven by weight loss, reduced inflammation, and direct metabolic improvements.
- Several specific cancers show clear protection, particularly liver, colorectal, endometrial, and ovarian cancers.
- Thyroid cancer remains a monitored concern, but the absolute risk is small and the evidence is not conclusive. If you have a personal or family history of medullary thyroid cancer or MEN 2, GLP-1 medications are contraindicated.
- Continue standard cancer screenings as recommended by your physician. GLP-1 medications do not replace or modify standard screening guidelines.
As with all medications, the decision to use a GLP-1 involves weighing benefits against risks in your specific clinical context. For the vast majority of patients, the cardiovascular, metabolic, and weight-loss benefits far outweigh the currently identified cancer-related risks. Discuss any concerns with your healthcare provider.
Sources
- Dai H, et al. “GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.” JAMA Oncology. 2025;11(10):1186-1193.
- Silverii GA, et al. “GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.” Diabetes Obes Metab. 2025;27(8):4454-4468.
- Vilsbøll T, et al. “Assessment of thyroid cancer risk associated with GLP-1RA use.” Diabetes Obes Metab. 2026.
- JCI Review. “GLP-1 receptor agonists and cancer: current clinical evidence.” 2025.
- Pasta A, et al. Meta-analysis of GLP-1RA and hepatocellular carcinoma risk. Multiple studies.